NCT04624958View on ClinicalTrials.gov

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Mantle Cell LymphomaNewly-diagnosed Mantle Cell Lymphoma
Interventions
DRUG

Zanubrutinib and Rituximab

Zanubrutinb 160mg PO BID d1-28; Rituximab 375mg/m2 iv.drip d1.

DRUG

R-DHAOx

Rituximab 375mg/m2 iv.drip d1; Dexamethasone 20mg iv.drip d1-4; Cytarabine 2000mg/m2 (1000mg/m2 for patients aged over 65) iv.drip d2,3 Oxaliplatin 130mg/m2 iv.drip d1.

DRUG

Zanubrutinib Maintenance

Zanubrutinb 160mg PO BID.

Trial Locations (3)

510000

Guangdong General Hospital, Guangzhou

510060

Sun Yat-sen University Cancer Center, Guangzhou

The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER